Humberto Quintana

Summary

Affiliation: Louisiana State University Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint An open-label study of olanzapine in children and adolescents with schizophrenia
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Psychiatr Pract 13:86-96. 2007
  2. ncbi request reprint Transcranial magnetic stimulation in persons younger than the age of 18
    Humberto Quintana
    Department of Psychiatry, Division of Child and Adolescent Psychiatry, Louisiana State University Health Science Center, School of Medicine, New Orleans, Louisiana 70112 2822, USA
    J ECT 21:88-95. 2005
  3. ncbi request reprint Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center School of Medicine at New Orleans, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Child Psychiatry Hum Dev 37:241-53. 2007
  4. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
  5. ncbi request reprint Comparison of a standard psychiatric evaluation to rating scales and EEG in the differential diagnosis of attention-deficit/hyperactivity disorder
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Room 314a, New Orleans, LA 70112, USA
    Psychiatry Res 152:211-22. 2007
  6. doi request reprint Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
  7. ncbi request reprint Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    Christopher J Kratochvil
    Department of Psychiatry, Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:915-24. 2005
  8. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
  9. ncbi request reprint Cardiovascular effects of atomoxetine in children, adolescents, and adults
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Saf 26:729-40. 2003
  10. doi request reprint Blinded, multi-center validation of EEG and rating scales in identifying ADHD within a clinical sample
    Steven M Snyder
    Department of Psychology, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA
    Psychiatry Res 159:346-58. 2008

Detail Information

Publications12

  1. ncbi request reprint An open-label study of olanzapine in children and adolescents with schizophrenia
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Psychiatr Pract 13:86-96. 2007
    ..Weight gain was significant, with patients averaging a gain of about 6.2 kg during the 6-week course of the study. Two of the subjects experienced extrapyramidal symptoms. The average dose of olanzapine for all subjects was 0.17 mg/kg...
  2. ncbi request reprint Transcranial magnetic stimulation in persons younger than the age of 18
    Humberto Quintana
    Department of Psychiatry, Division of Child and Adolescent Psychiatry, Louisiana State University Health Science Center, School of Medicine, New Orleans, Louisiana 70112 2822, USA
    J ECT 21:88-95. 2005
    ..I discuss the technical differences, as well as the diagnostic, therapeutic, and psychiatric uses of TMS/rTMS in this age group...
  3. ncbi request reprint Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center School of Medicine at New Orleans, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Child Psychiatry Hum Dev 37:241-53. 2007
    ....
  4. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
    ..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied...
  5. ncbi request reprint Comparison of a standard psychiatric evaluation to rating scales and EEG in the differential diagnosis of attention-deficit/hyperactivity disorder
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Room 314a, New Orleans, LA 70112, USA
    Psychiatry Res 152:211-22. 2007
    ..In the detection of ADHD in a diverse clinical sample, rating scales and EEG were both sensitive markers, whereas only EEG was specific. These results may have important implications to ADHD differential diagnosis...
  6. doi request reprint Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
    ....
  7. ncbi request reprint Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    Christopher J Kratochvil
    Department of Psychiatry, Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:915-24. 2005
    ..The authors assessed the safety and effectiveness of atomoxetine monotherapy compared with combined atomoxetine/fluoxetine therapy in a population of children and adolescents with ADHD and concurrent symptoms of depression or anxiety...
  8. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
    ..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD...
  9. ncbi request reprint Cardiovascular effects of atomoxetine in children, adolescents, and adults
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Saf 26:729-40. 2003
    ..Adverse effects on the cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac rhythm have been associated with several noradrenergic medications...
  10. doi request reprint Blinded, multi-center validation of EEG and rating scales in identifying ADHD within a clinical sample
    Steven M Snyder
    Department of Psychology, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA
    Psychiatry Res 159:346-58. 2008
    ....
  11. ncbi request reprint Review of clinical validation of ADHD behavior rating scales
    Steven M Snyder
    University of North Texas Health Science Center at Fort Worth, USA
    Psychol Rep 99:363-78. 2006
    ..We recommend further research following the full AAN standards, namely well-designed, blinded, pro spective studies of rating scales applied to clinically representative samples evaluated with a clinical standard...
  12. ncbi request reprint Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
    ..Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms...